Biotech stocks have started to wake up, and one of our favorites is making a move. Sarepta Therapeutics is a biotech company from Cambridge, MA. If you’ve never heard of it, you’re in good company. It’s a big-time player in the biotech sector, and it’s only a matter of time before this company is noticed. The big money is starting to flow into Sarepta.
The chart is solid and constructive. On Monday, it broke out of its range on expanded volume. A follow-through day would be ideal, and a move past the 200 ma would allow the gap (around 145) to be filled. Money flow is strong, and the MACD is on a buy signal.
I have been long this name for a while (Aug, Oct and Jan 130 and 150 strikes), and I really like the strong momentum here.
Take a deeper dive into Sarepta Therapeutics chart action (Nasdaq: SRPT) and learn how to read the technicals. Get Bob Lang’s full analysis as he marks up our chart of the week.
Love what you’re learning in our market analysis? Don’t miss a single video! Get the latest chart action delivered directly to your inbox every week as Bob breaks down stocks to watch and potential trade options!
About Sarepta Therapeutics (SRPT)
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. Sarepta was founded in 1980 and is headquartered in Cambridge, Massachusetts.